ND1

General Information


DRACP ID  DRACP01109

Peptide Name   ND1

Sequence  GLFDIWKGIKSLF

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Hep-G2 Hepatoblastoma; Hepatoblastoma Blastoma IC50=102.33±1.45 µg/mL MTT assay 24h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Vero: IC50=22.67±0.44 µg/mL; THLE-3: IC50=34.33±0.73 µg/mL

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01109

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C76H114N16O17

Absent amino acids  ACEHMNPQRTVY

Common amino acids  FGIKL

Mass  173807

Pl  9.54

Basic residues  2

Acidic residues  1

Hydrophobic residues  7

Net charge  1

Boman Index  663

Hydrophobicity  64.62

Aliphatic Index  120

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  458.33

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Hybrid Anticancer Peptides DN1 and DN4 Exert Selective Cytotoxicity Against Hepatocellular Carcinoma Cells by Inducing Both Intrinsic and Extrinsic Apoptotic Pathways

Doi 10.1007/s10989-021-10288-8

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.